LivaNova delivered a clean beat on the metrics Wall Street watches. Adjusted earnings of $1.23 per share topped the $1.03 consensus by 12.8% and cleared the $1.09 Earnings Whisper number. Revenue of $393.1 million beat the $380.07 million estimate by 3.4%. On Earnings Whispers' normalized basis, earnings grew 26.8% year over year and revenue rose 9.9%; the company's own adjusted EPS comparison was $1.23 against $1.11. The more important development is the third consecutive raise to every top-line guide. Full-year constant-currency revenue growth is now 9% to 10%, 300 basis points above the original 6% to 7%. Adjusted EPS guidance moved up $0.10 to $4.40 to $4.50, against an initial $4.15 to $4.25. The central tension is that the revenue story keeps strengthening while cash flow, the operating-margin framework and the implied fourth quarter have not moved with it.
The top line was broad and high quality. Cardiopulmonary grew 10.9% to $225.3 million, with growth in every region. Management said consumables accelerated to low double digits from high single digits in Q2, and heart-lung machines benefited from record quarterly Essenz placements. Neuromodulation rose 11.1% to $166.1 million. Management cited epilepsy growth of 11%, accelerating from 8% in Q1 and 10% in Q2, and U.S. epilepsy improved to 10% from 7% and 8% earlier in the year. Pricing is doing real work: realized price is running about twice the normal annual increase. Management expects residual epilepsy contract renegotiations to add price in 2027 and plans premium pricing for the next-generation IPG. Total growth was modestly held back by the prior-year $3.1 million Italian payback reserve release in Other revenue.
The quality of the margin beat deserves scrutiny. Adjusted operating margin expanded to 23.5% from 22.5%, but adjusted gross margin was essentially flat at 69.3%. Nearly all the leverage came from R&D, which fell to 11.4% of revenue from 12.6%. Management acknowledged that sleep apnea spending shifted into Q4, so part of the upside is timing rather than structural improvement. That explains why the 20% to 21% full-year operating-margin guide never moved. It also explains why 2027 is framed only as "above 20%." GAAP results look starkly different. Diluted EPS fell to $0.11 from $0.49 and GAAP operating income dropped to $28.4 million, driven by $34.0 million of other operating expense tied mainly to the 3T heater-cooler litigation provision. A $28.2 million gain on the 2029 notes conversion option was also removed from the diluted numerator.
Cash flow is where bears have legitimate ammunition. Adjusted free cash flow slipped to $55.8 million from roughly $62 million a year ago. Nine-month capex climbed to $76.6 million from $48.8 million, and full-year free cash flow guidance stayed at $140 million to $160 million despite the EPS raise, after being cut from $160 million to $180 million in Q2. The roughly $400 million SNIA environmental payment slipped from Q3 into Q4. That liability, carried at $383.6 million, will absorb most of the $563.5 million cash balance when it is paid. The implied fourth quarter also points to deceleration against difficult Essenz capital comparisons.
The forward catalysts are substantive. The dedicated oxygenator line is now operational, and together with the Thermo Fisher supply agreement it supports management's target of double-digit oxygenator output growth in 2027. In obstructive sleep apnea, the AMA established Category I CPT codes covering LivaNova's proximal hypoglossal nerve stimulation therapy, effective January 2028. Next-generation platform verification is on track, and a limited launch is planned for 2027. The risk is that management also described a slowing near-term HGNS market clouded by reimbursement confusion. Separately, the full 36-month CORE-VNS results showed a 76% median seizure reduction, reinforcing the epilepsy franchise.
The market had largely priced in strength. Shares closed at $79.90 before the report, essentially unchanged from the $79.88 open after the August release. The stock sat 9.4% above its 200-day moving average and 4.3% below its September high of $83.52, after rebounding from a late-September low of $74.11. Investor sentiment edged up from slightly negative to slightly positive, a shift too small to signal strong conviction either way. Momentum and AVWAP trend readings are positive, while price trend is neutral.
The bottom line is that LivaNova keeps proving its core cardiopulmonary and epilepsy franchises are growing faster than anyone expected, and the call preserved a credible multi-year sleep apnea story. The upgrade, however, is concentrated in revenue and adjusted EPS. Margins are flattered by R&D timing, free cash flow guidance remains stuck below its original level, and a large SNIA cash outflow and a tougher Q4 comparison are still ahead.